Mykofenolan Mofetylu Accord (Mycophenolate Mofetil)

Mycophenolate mofetil selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks the de novo synthesis of guanine nucleotides, a pathway essential for the proliferation of activated T and B lymphocytes. By limiting lymphocyte replication, the drug dampens the immune response that can lead to graft rejection.

The exact dose and infusion schedule are set by the prescribing physician based on the type of transplant, the patient’s weight, renal function, and concomitant immunosuppressive therapy. Dosing is individualized and should follow the clinician’s assessment and local transplant protocol.

Mycophenolate mofetil is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended, as the drug is excreted in milk and may affect the infant. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Mycophenolate mofetil offers a more selective inhibition of lymphocyte proliferation compared with azathioprine, which affects broader nucleic acid synthesis pathways. Clinically, mycophenolate is often associated with lower rates of acute rejection but may have a different side‑effect profile, including higher rates of gastrointestinal upset and leukopenia. Choice of agent depends on the transplant protocol and patient tolerance.

The product should be stored at temperatures not exceeding 25 °C, in its original packaging, protected from moisture and direct light. Once reconstituted for infusion, it must be used within the time frame specified in the product label and kept under the same temperature conditions.

Mykofenolan Mofetylu Accord is supplied as an injectable solution for intravenous infusion. The infusion is typically given over a period of 30 minutes to several hours, depending on the prescribing protocol. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious risks include opportunistic infections such as Pneumocystis jirovecii pneumonia, development of malignancies (especially lymphoproliferative disorders), severe hepatic injury, progressive multifocal leukoencephalopathy, and bone‑marrow failure leading to aplastic anemia or pancytopenia. Patients should be monitored closely for signs of infection, abnormal liver tests and blood‑cell counts.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the product. It is also contraindicated in pregnant women, individuals with uncontrolled severe infections, and those with severe hepatic impairment unless the benefit outweighs the risk and close monitoring is possible.